However, there have been no reports comparing the abilities of the anti-inflammatory IL-6 inhibitor (Tocilizumab) and TNF-α inhibitor (Infliximab and Etanercept) to inhibit CML-induced inflammation in a hyperlipidemic state. This evidence concerns the gene TNF and chronic myelogenous leukemia, BCR-ABL1 positive.